Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR~* Willingness and ability to comply with scheduled visits, treatment plan and procedures~Exclusion Criteria:~* Subject requires precaution against suicide~* Subject not in a generally healthy condition

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine Succinate Sustained-Release (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).